{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T13:41:38Z","timestamp":1781790098284,"version":"3.54.5"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T00:00:00Z","timestamp":1730246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T00:00:00Z","timestamp":1730246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s40261-024-01403-w","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T16:27:21Z","timestamp":1730305641000},"page":"839-847","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A Pilot Study of the Effectiveness of a Short Course of Rifaximin 2200 mg\/day on Abdominal Symptoms and its Effects on Quality of Life in Patients with Moderate to Severe Diarrhea-Predominant Irritable Bowel Syndrome"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4869-9442","authenticated-orcid":false,"given":"Marjan","family":"Mokhtare","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Fathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir M.","family":"Sadeghian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad-Javad","family":"Sotoudeheian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abolfazl","family":"Namazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,30]]},"reference":[{"key":"1403_CR1","doi-asserted-by":"publisher","first-page":"175628481989753","DOI":"10.1177\/1756284819897531","volume":"13","author":"WD Chey","year":"2020","unstructured":"Chey WD, Shah ED, DuPont HL. Mechanism of action and therapeutic benefit of rifaximin in patients with irritable bowel syndrome: a narrative review. Ther Adv Gastroenterol. 2020;13:1756284819897531. https:\/\/doi.org\/10.1177\/1756284819897531.","journal-title":"Ther Adv Gastroenterol"},{"key":"1403_CR2","doi-asserted-by":"publisher","first-page":"4003","DOI":"10.1007\/s12325-022-02224-z","volume":"39","author":"B Moshiree","year":"2022","unstructured":"Moshiree B, Heidelbaugh JJ, Sayuk GS. A narrative review of irritable bowel syndrome with diarrhea: a primer for primary care providers. Adv Ther. 2022;39:4003\u201320. https:\/\/doi.org\/10.1007\/s12325-022-02224-z.","journal-title":"Adv Ther"},{"key":"1403_CR3","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.3389\/fmicb.2018.01600","volume":"9","author":"X Zhuang","year":"2018","unstructured":"Zhuang X, Tian Z, Li L, et al. Fecal microbiota alterations associated with diarrhea-predominant irritable bowel syndrome. Front Microbiol. 2018;9:1600. https:\/\/doi.org\/10.3389\/fmicb.2018.01600.","journal-title":"Front Microbiol"},{"key":"1403_CR4","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.3390\/nu13093061","volume":"13","author":"MNM Aziz","year":"2021","unstructured":"Aziz MNM, Kumar J, Muhammad Nawawi KN, et al. Irritable bowel syndrome, depression, and neurodegeneration: a bidirectional communication from gut to brain. Nutrients. 2021;13:3061. https:\/\/doi.org\/10.3390\/nu13093061.","journal-title":"Nutrients"},{"key":"1403_CR5","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s40265-023-01871-y","volume":"83","author":"VC Goodoory","year":"2023","unstructured":"Goodoory VC, Ford AC. Antibiotics and probiotics for irritable bowel syndrome. Drugs. 2023;83:687\u201399. https:\/\/doi.org\/10.1007\/s40265-023-01871-y.","journal-title":"Drugs"},{"key":"1403_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2020.00664","volume":"11","author":"W Takakura","year":"2020","unstructured":"Takakura W, Pimentel M. Small intestinal bacterial overgrowth and irritable bowel syndrome\u2013an update. Front Psychiatry. 2020;11: 558965. https:\/\/doi.org\/10.3389\/fpsyt.2020.00664.","journal-title":"Front Psychiatry."},{"key":"1403_CR7","first-page":"140","volume":"19","author":"J Lim","year":"2023","unstructured":"Lim J, Rezaie A. Pros and cons of breath testing for small intestinal bacterial overgrowth and intestinal methanogen overgrowth. Gastroenterol Hepatol. 2023;19:140.","journal-title":"Gastroenterol Hepatol"},{"key":"1403_CR8","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.14309\/ajg.0000000000001997","volume":"117","author":"MJ Villanueva-Millan","year":"2022","unstructured":"Villanueva-Millan MJ, Leite G, Wang J, et al. Methanogens and hydrogen sulfide producing bacteria guide distinct gut microbe profiles and irritable bowel syndrome subtypes. Am J Gastroenterol. 2022;117:2055\u201366. https:\/\/doi.org\/10.14309\/ajg.0000000000001997.","journal-title":"Am J Gastroenterol"},{"key":"1403_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.genhosppsych.2023.01.004","volume":"81","author":"EN Madva","year":"2023","unstructured":"Madva EN, Sadlonova M, Harnedy LE, et al. Positive psychological well-being and clinical characteristics in IBS: a systematic review. Gen Hosp Psychiatry. 2023;81:1\u201314. https:\/\/doi.org\/10.1016\/j.genhosppsych.2023.01.004.","journal-title":"Gen Hosp Psychiatry"},{"key":"1403_CR10","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1017\/S0033291716001987","volume":"46","author":"A Sibelli","year":"2016","unstructured":"Sibelli A, Chalder T, Everitt H, Workman P, Windgassen S, Moss-Morris R. A systematic review with meta-analysis of the role of anxiety and depression in irritable bowel syndrome onset. Psychol Med. 2016;46:3065\u201380.","journal-title":"Psychol Med"},{"key":"1403_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104527","author":"L Liu","year":"2023","unstructured":"Liu L, Wang H, Chen X, et al. Gut microbiota and its metabolites in depression: from pathogenesis to treatment. EBioMedicine. 2023. https:\/\/doi.org\/10.1016\/j.ebiom.2023.104527.","journal-title":"EBioMedicine"},{"key":"1403_CR12","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/apt.17132","volume":"56","author":"VC Goodoory","year":"2022","unstructured":"Goodoory VC, Ng CE, Black CJ, et al. Impact of Rome IV irritable bowel syndrome on work and activities of daily living. Aliment Pharmacol Ther. 2022;56:844\u201356. https:\/\/doi.org\/10.1111\/apt.17132.","journal-title":"Aliment Pharmacol Ther"},{"key":"1403_CR13","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1177\/1756283X17726087","volume":"10","author":"BD Cash","year":"2017","unstructured":"Cash BD, Pimentel M, Rao SS, et al. Repeat treatment with rifaximin improves irritable bowel syndrome-related quality of life: a secondary analysis of a randomized, double-blind, placebo-controlled trial. Ther Adv Gastroenterol. 2017;10:689\u201399. https:\/\/doi.org\/10.1177\/1756283X17726087.","journal-title":"Ther Adv Gastroenterol"},{"key":"1403_CR14","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/apt.17356","volume":"57","author":"VC Goodoory","year":"2023","unstructured":"Goodoory VC, Guthrie EA, Ng CE, et al. Factors associated with lower disease-specific and generic health-related quality of life in Rome IV irritable bowel syndrome. Aliment Pharmacol Ther. 2023;57:323\u201334. https:\/\/doi.org\/10.1111\/apt.17356.","journal-title":"Aliment Pharmacol Ther"},{"key":"1403_CR15","doi-asserted-by":"publisher","first-page":"4230","DOI":"10.3390\/ijerph17124230","volume":"17","author":"R Sier\u017cantowicz","year":"2020","unstructured":"Sier\u017cantowicz R, Lewko J, Jurkowska G. The impact of an individual educational program on the quality of life and severity of symptoms of patients with irritable bowel syndrome. Int J Environ Res Public Health. 2020;17:4230. https:\/\/doi.org\/10.3390\/ijerph17124230.","journal-title":"Int J Environ Res Public Health"},{"key":"1403_CR16","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.44807","author":"Z Khan","year":"2023","unstructured":"Khan Z, Khan SK, Reyaz I, et al. Effectiveness of rifaximin on the outcomes of irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. Cureus. 2023. https:\/\/doi.org\/10.7759\/cureus.44807.","journal-title":"Cureus."},{"key":"1403_CR17","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1111\/apt.17736","volume":"58","author":"K Staller","year":"2023","unstructured":"Staller K, Ol\u00e9n O, S\u00f6derling J, et al. Antibiotic use as a risk factor for irritable bowel syndrome: results from a nationwide, case\u2013control study. Aliment Pharmacol Ther. 2023;58:1175\u201384. https:\/\/doi.org\/10.1111\/apt.17736.","journal-title":"Aliment Pharmacol Ther"},{"key":"1403_CR18","doi-asserted-by":"publisher","first-page":"92","DOI":"10.15403\/jgld-4871","volume":"32","author":"A Gasbarrini","year":"2023","unstructured":"Gasbarrini A, Ponziani FR, Ianiro G, et al. Update on the role of Rifaximin in digestive diseases. J Gastrointest Liver Dis. 2023;32:92\u2013109. https:\/\/doi.org\/10.15403\/jgld-4871.","journal-title":"J Gastrointest Liver Dis"},{"key":"1403_CR19","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1177\/019394591987241","volume":"42","author":"LB Sherwin","year":"2020","unstructured":"Sherwin LB, Deroche CB, Krisanabud P, et al. Adherence to short-course pharmacotherapy in adults with irritable bowel syndrome. West J Nurs Res. 2020;42:524\u201334. https:\/\/doi.org\/10.1177\/019394591987241.","journal-title":"West J Nurs Res"},{"key":"1403_CR20","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1097\/j.pain.0000000000002234","volume":"162","author":"A Lembo","year":"2021","unstructured":"Lembo A, Kelley JM, Nee J, et al. Open-label placebo vs double-blind placebo for irritable bowel syndrome: a randomized clinical trial. Pain. 2021;162:2428\u201335. https:\/\/doi.org\/10.1097\/j.pain.0000000000002234.","journal-title":"Pain"},{"key":"1403_CR21","doi-asserted-by":"publisher","DOI":"10.14309\/ctg.0000000000000144","volume":"11","author":"A Lembo","year":"2020","unstructured":"Lembo A, Rao SS, Heimanson Z, et al. Abdominal pain response to rifaximin in patients with irritable bowel syndrome with diarrhea. Clin Transl Gastroenterol. 2020;11: e00144. https:\/\/doi.org\/10.14309\/ctg.0000000000000144.","journal-title":"Clin Transl Gastroenterol"},{"key":"1403_CR22","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.clinthera.2023.01.010","volume":"45","author":"BE Lacy","year":"2023","unstructured":"Lacy BE, Chang L, Rao SS, et al. Rifaximin treatment for individual and multiple symptoms of irritable bowel syndrome with diarrhea: an analysis using new end points. Clin Ther. 2023;45:198\u2013209. https:\/\/doi.org\/10.1016\/j.clinthera.2023.01.010.","journal-title":"Clin Ther"},{"key":"1403_CR23","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1111\/jgh.13841","volume":"33","author":"Y Jin","year":"2018","unstructured":"Jin Y, Ren X, Li G, et al. Beneficial effects of Rifaximin in post-infectious irritable bowel syndrome mouse model beyond gut microbiota. J Gastroenterol Hepatol. 2018;33:443\u201352. https:\/\/doi.org\/10.1111\/jgh.13841.","journal-title":"J Gastroenterol Hepatol"},{"key":"1403_CR24","doi-asserted-by":"publisher","DOI":"10.2147\/CEG.S18051","author":"J Jolley","year":"2011","unstructured":"Jolley J. High-dose rifaximin treatment alleviates global symptoms of irritable bowel syndrome. Clin Exp Gastroenterol. 2011. https:\/\/doi.org\/10.2147\/CEG.S18051.","journal-title":"Clin Exp Gastroenterol"},{"key":"1403_CR25","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1111\/apt.12735","volume":"39","author":"P Schoenfeld","year":"2014","unstructured":"Schoenfeld P, Pimentel M, Chang L, et al. Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials. Aliment Pharmacol Ther. 2014;39:1161\u20138. https:\/\/doi.org\/10.1111\/apt.12735.","journal-title":"Aliment Pharmacol Ther"},{"key":"1403_CR26","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/ygh2.416","volume":"2","author":"SD Lee","year":"2020","unstructured":"Lee SD, Singla A, Rulyak SJ, et al. Double-blind, randomised, placebo-controlled crossover trial to evaluate the clinical efficacy of rifaximin in patients with moderate to severe active Crohn\u2019s disease. GastroHep. 2020;2:185\u201392. https:\/\/doi.org\/10.1002\/ygh2.416.","journal-title":"GastroHep."},{"issue":"473\u2013481","key":"1403_CR27","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.11.032","volume":"142","author":"C Prantera","year":"2012","unstructured":"Prantera C, Lochs H, Grimaldi M, et al. Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn\u2019s disease. Gastroenterol. 2012;142(473\u2013481): e474. https:\/\/doi.org\/10.1053\/j.gastro.2011.11.032.","journal-title":"Gastroenterol"},{"key":"1403_CR28","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000024059","volume":"100","author":"C Tocia","year":"2021","unstructured":"Tocia C, Dumitru IM, Alexandrescu L, et al. Does rifaximin offer any promise in Crohn\u2019s disease in remission and concurrent irritable bowel syndrome-like symptoms? Medicine. 2021;100: e24059. https:\/\/doi.org\/10.1097\/MD.0000000000024059.","journal-title":"Medicine"},{"key":"1403_CR29","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1177\/2374373519882230","volume":"7","author":"LB Sherwin","year":"2020","unstructured":"Sherwin LB, Ross D, Matteson-Kome M, et al. Patient perspectives on short-course pharmacotherapy: barriers and facilitators to medication adherence. J Patient Exp. 2020;7:726\u201333. https:\/\/doi.org\/10.1177\/2374373519882230.","journal-title":"J Patient Exp."},{"key":"1403_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12876-020-01336-6","volume":"20","author":"X Zhuang","year":"2020","unstructured":"Zhuang X, Tian Z, Luo M, et al. Short-course rifaximin therapy efficacy and lactulose hydrogen breath test in Chinese patients with diarrhea-predominant irritable bowel syndrome. BMC gastroenterol. 2020;20:1\u201310. https:\/\/doi.org\/10.1186\/s12876-020-01336-6.","journal-title":"BMC gastroenterol"},{"issue":"7","key":"1403_CR31","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1002\/ueg2.12277","volume":"10","author":"C Melchior","year":"2022","unstructured":"Melchior C, Colomier E, Trindade IA, Khadija M, Hreinsson JP, T\u00f6rnblom H, Simr\u00e9n M. Irritable bowel syndrome: factors of importance for disease-specific quality of life. United Eur Gastroenterol J. 2022;10(7):754\u201364. https:\/\/doi.org\/10.1002\/ueg2.12277.","journal-title":"United Eur Gastroenterol J."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-024-01403-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-024-01403-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-024-01403-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T12:44:31Z","timestamp":1731588271000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-024-01403-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,30]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["1403"],"URL":"https:\/\/doi.org\/10.1007\/s40261-024-01403-w","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,30]]},"assertion":[{"value":"14 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Marjan Mokhtare, Maryam Fathi<sub>,<\/sub> Amir M. Sadeghian, Mohammad-Javad Sotoudeheian, and Abolfazl Namazi have no conflicts of interest that are directly relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The authors declare that no funds, grants, or other support were received during the preparation of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"This study and all study-related procedures were approved by the medical ethics committee of Iran University of Medical Sciences, Tehran, Iran (approval date 2023-06-11; ethics committee reference number: IR.IUMS.FMD.REC.1402.135) and so registered in the Iranian Registry of Clinical Trials (IRCT20141201020178N12).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}},{"value":"The data used in this study are accessible upon a reasonable request to the corresponding author.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to the study's conception and design. Marjan Mokhtare, Maryam Fathi, Amir M. Sadeghian, and Mohammad-Javad Sotoudeheian prepared the material and collected and analyzed the data. Marjan Mokhtare and Abolfazl Namazi wrote the first draft of the manuscript, and all authors commented on subsequent versions. All authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}